Who makes Hyaluronan binding system?

Hyaluronan binding system is developed by ClinAmygate.

What development phase is Hyaluronan binding system in?

Hyaluronan binding system is FDA-approved (marketed).

Last reviewed 2026-04-22 · How we verify

Hyaluronan binding system

ClinAmygate · FDA-approved active Biologic

A hyaluronan-based delivery system that binds to hyaluronan receptors to facilitate targeted drug or therapeutic agent delivery.

At a glance

Generic name	Hyaluronan binding system
Sponsor	ClinAmygate
Drug class	Drug delivery system / Biopolymer conjugate
Target	Hyaluronan receptors (e.g., CD44)
Modality	Biologic
Phase	FDA-approved

Mechanism of action

Hyaluronan binding systems leverage the natural affinity of hyaluronan (a glycosaminoglycan) for its receptors (such as CD44) present on target cells. This approach enables selective accumulation of therapeutics at disease sites while potentially reducing systemic exposure. The system is designed to improve bioavailability and therapeutic efficacy of conjugated or encapsulated payloads.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Sperm Selection Technique Using Hyaluronic Acid Binding in Intra-cytoplasmic Sperm Injection (ICSI) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results